Advertisement

Journal of Neurology

, Volume 256, Issue 10, pp 1771–1772 | Cite as

Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis

  • Azza Ismail
  • Julie Kemp
  • Basil SharrackEmail author
Letter to the Editors

Sirs,

Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a humanized monoclonal antibody which targets the α4 subunits of the cellular adhesion molecules α4β1 and α4β7 integrins, blocking their interaction with their co-receptors VCAM-1, CS-1 and MadCAM-1 [3, 15]. This action reduces leukocyte trafficking into the brain and gut and mediates the beneficial effect of natalizumab in multiple sclerosis (MS) and Crohn’s disease [3]. The efficacy of natalizumab in patients with relapsing remitting MS was demonstrated in two phase III studies, AFFIRM and SENTINAL [10, 12]. These studies showed that when natalizumab was used as mono therapy or in combination with interferon beta-1a (Avonex) it significantly reduced relapse rate and slowed the progression of disability. Natalizumab was well tolerated with the most common adverse effects being headache, infusion reactions and a modest increase in urinary and respiratory tract infections [10, 12]. Neither trial identified any...

Keywords

Melanoma Multiple Sclerosis Progressive Multifocal Leukoencephalopathy Natalizumab Progressive Multifocal Leukoencephalopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest statement

None.

References

  1. 1.
    Adelman B, Sandrock A, Panzara MA (2005) Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 353:432–433PubMedCrossRefGoogle Scholar
  2. 2.
    Bauer R, Humphries M, Fassler R, Winklmeier A, Craig SE, Bossehoff AK (2006) Regulation of integrin activity by MIA. J Biol Chem 281:11669–11677PubMedCrossRefGoogle Scholar
  3. 3.
    Davenpor RJ, Munday JR (2007) Alpha4-integrin antagonism—an effective approach for the treatment of inflammatory diseases? Drug Discov Today 12(13-14):569CrossRefGoogle Scholar
  4. 4.
  5. 5.
    Kedl RM, Mescher MF (1997) Migration and activation of antigen-specific CD8+ T cells upon in vivo stimulation with allogeneic tumour. J Immunol 159:650–663PubMedGoogle Scholar
  6. 6.
    Larouche N, Larouche K, Be’liveau A et al (1998) Transcriptional regulation of the alpha 4-integrin subunit gene in the metastatic spread of uveal melanoma. Anticancer Res 18(5a):3539–3547PubMedGoogle Scholar
  7. 7.
    Mullen JT, Vartanian TK, Atkins MB (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358(6):647–648PubMedCrossRefGoogle Scholar
  8. 8.
    Ogawa M, Tsutsui T, Zou JP et al (1997) Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumour sites following administration of interleukin 12. Cancer Res 57:2216–2222PubMedGoogle Scholar
  9. 9.
    Panzara MA, Bozic C, Sandrock AW (2008) More on melanoma with transdifferentiation. N Engl J Med 359(1):99PubMedCrossRefGoogle Scholar
  10. 10.
    Polman CH, O’Connor PW, Havrdova E et al (2006) A randomised placebo- controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med 354:899–910CrossRefGoogle Scholar
  11. 11.
    Qian F, Vaux DL, Weissman IL (1994) Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell 77(3):335–347PubMedCrossRefGoogle Scholar
  12. 12.
    Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923PubMedCrossRefGoogle Scholar
  13. 13.
    Stüve O, Marra CM, Bar-Or A et al (2006) Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63(10):1383–1387PubMedCrossRefGoogle Scholar
  14. 14.
    Ulrich C, Schmook T, Sachse MM et al (2004) Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 30:622–627PubMedCrossRefGoogle Scholar
  15. 15.
    Yang Y, Cardarelli PM, Lehnert K et al (1998) LPAM-1 (integrin alpha 4 beta 7)-ligand binding: overlapping binding sites recognizing VCAM-1, MAdCAM-1 and CS-1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides. Eur J Immunol 28(3):995–1004PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of NeurologyRoyal Hallamshire HospitalSheffieldUK

Personalised recommendations